SAN DIEGO, Calif., July 14, 2026
Atrium Therapeutics has achieved an important regulatory milestone after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for ATR 1072, enabling the company to initiate the Corventis™ Phase 1/2 clinical trial for patients with PRKAG2 syndrome, a rare inherited cardiomyopathy with no approved disease-modifying therapies. The FDA clearance marks the first time a clinical study will evaluate a therapy designed to target the underlying genetic cause of PRKAG2 syndrome rather than managing symptoms alone. ATR 1072 is the company’s lead precision RNA therapeutic, utilizing small interfering RNA (siRNA) technology to selectively silence mutant PRKAG2 messenger RNA (mRNA), normalize abnormal AMP-activated protein kinase (AMPK) activity, and reduce harmful glycogen accumulation in the heart. The milestone positions Atrium Therapeutics at the forefront of precision cardiology, advancing innovative RNA-based therapies for genetically driven cardiovascular diseases with significant unmet medical need. Clinical site initiation activities are already underway, with the company expecting to enroll the first patient before the end of 2026, while initial proof-of-concept data are anticipated during the second half of 2027.
FDA Clearance Launches First Precision Trial for PRKAG2 Syndrome
The Corventis™ Phase 1/2 clinical trial represents a historic step for patients living with PRKAG2 syndrome, becoming the first clinical study specifically evaluating a therapy designed to treat the disease’s underlying molecular cause. The multicenter, open-label study will enroll approximately 37 participants across two sequential stages. Part A will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics using multiple ascending-dose cohorts to determine the optimal therapeutic dose, while Part B will further investigate safety, efficacy, and improvements in cardiac structure and function at the recommended Phase 2 dose. By focusing on disease modification instead of symptom control, Atrium aims to transform treatment for patients affected by this progressive inherited cardiomyopathy, which frequently causes abnormal heart muscle thickening, electrical conduction disorders, arrhythmias, and heart failure. Currently, available medical management is limited to treating complications, highlighting the urgent need for innovative therapies capable of addressing the genetic driver of disease.
RNA Therapeutics Advance Precision Cardiology
ATR 1072 leverages Atrium Therapeutics’ proprietary targeted RNA delivery platform, combining tissue-selective delivery with small interfering RNA (siRNA) technology to specifically silence disease-causing genetic mutations within the heart. By reducing expression of the mutant PRKAG2 gene, the investigational therapy is designed to normalize AMPK signaling, decrease pathological glycogen accumulation, and ultimately improve cardiac function. This precision medicine strategy represents a new generation of cardiovascular therapeutics capable of targeting the molecular mechanisms responsible for inherited heart diseases. In addition to ATR 1072, Atrium is developing ATR 1086 for phospholamban (PLN) cardiomyopathy alongside several additional research programs targeting rare genetic cardiomyopathies. Together, these programs reinforce the company’s commitment to advancing RNA therapeutics capable of addressing diseases that currently lack effective treatment options while expanding the role of genetic medicine in cardiovascular care.
Advertisement
Clinical Development Expands Rare Disease Innovation
The FDA’s clearance of ATR 1072 underscores the growing momentum behind RNA-based therapeutics and precision medicine approaches for rare cardiovascular disorders. With an estimated 1,000 to 2,000 patients in the United States affected by PRKAG2 syndrome, successful development of ATR 1072 could establish the first disease-modifying treatment for this life-threatening inherited condition. Beyond its clinical significance, the program also demonstrates the expanding application of RNA interference technologies beyond liver and neuromuscular diseases into cardiovascular medicine. As Atrium Therapeutics advances enrollment in the Corventis™ trial, the company is helping redefine the future of precision cardiology by developing targeted therapies designed to correct the molecular abnormalities responsible for inherited heart disease. The FDA milestone therefore represents both an important advancement for patients with PRKAG2 syndrome and a significant step forward in the broader evolution of RNA therapeutics for cardiovascular disorders.
Source: Atrium Therapeutics press release
